Ramona Doyle compensation by year
RECURSION PHARMACEUTICALS Summary Compensation Table · all 3 fiscal years held| Component | FY2020 | FY2021 | FY2022 |
|---|---|---|---|
| Salary | $3,666 | $440,282 | $167,933 |
| Bonus | $0 | $0 | — |
| Stock awards | $0 | $0 | $475,848 |
| Option awards | $1,134,331 | $0 | $563,625 |
| Non-equity incentive | $0 | $154,000 | — |
| Pension and deferred compensation | $0 | $0 | — |
| All other | $0 | $13,174 | $359,058 |
| Total | $1,137,997 | $607,456 | $1,207,406 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: RECURSION PHARMACEUTICALS, INC. DEF 14A filed April 28, 2023, accession 0001601830-23-000013, and prior-year filings.
How this page was built: the RECURSION PHARMACEUTICALS, INC. filed document, accession 0001601830-23-000013. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2023.
RECURSION PHARMACEUTICALS’s named executive officers, FY2022
as the company reported each| Named executive officer | Role | FY2022 total |
|---|---|---|
| Christopher Gibson | Chief Executive Officer | $6,303,703 |
| Tina Marriott Larson | Chief Operating Officer and President | $2,750,640 |
| Michael Secora | Chief Financial Officer | $2,044,318 |
| Shafique Virani | Chief Corporate Development Office | $1,756,314 |
| Ramona Doyle · this page | Chief Medical Officer | $1,207,406 |
The full RECURSION PHARMACEUTICALS compensation record
free company briefThis page is one person within RECURSION PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the RECURSION PHARMACEUTICALS proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are RECURSION PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.